Article
Economics
Shanshan Hu, Xun Deng, Yanjiao Ma, Zhilei Li, Yuhang Wang, Yong Wang
Summary: The study evaluated the cost effectiveness of DAPA and SAXA as add-on therapy to MET in Chinese patients with inadequately controlled T2DM. Results showed that DAPA was a cost-effective option compared to DAPA + SAXA or SAXA alone, with favorable QALY gains and incremental costs per QALY. The pharmacoeconomic results were consistent across different sensitivity analyses.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY
(2021)
Article
Medicine, Research & Experimental
Zhongchao Wang, Jing Wang, Jianxia Hu, Ying Chen, Bingzi Dong, Yangang Wang
Summary: The study compared the efficacy and safety of acarbose, saxagliptin, and vildagliptin in treating T2DM, finding that these drugs can effectively reduce HbA1c levels and impact the distribution of intestinal flora in patients with T2DM. Adverse reactions were higher with saxagliptin compared to acarbose and vildagliptin, suggesting alternative strategies for the treatment of T2DM.
Review
Medicine, General & Internal
Ehtasham Ahmad, Soo Lim, Roberta Lamptey, David R. Webb, Melanie J. Davies
Summary: Type 2 diabetes accounts for nearly 90% of global diabetes cases, with an increasing number of affected individuals, particularly among young people. Early detection and proactive management are crucial for preventing complications and reducing mortality. Technology and precision medicine offer potential improvements to treatment outcomes but face significant barriers.
Article
Cardiac & Cardiovascular Systems
Tian Li, Rui Providencia, Nan Mu, Yue Yin, Mai Chen, Yishi Wang, Manling Liu, Lu Yu, Chunhu Gu, Heng Ma
Summary: This study found that T2DM patients treated with metformin did not show a lower risk of all-cause mortality or cardiovascular mortality compared to untreated T2DM patients. Further, the combination of metformin with another hypoglycemic drug was associated with a higher risk of all-cause and cardiovascular mortality.
CARDIOVASCULAR DIABETOLOGY
(2021)
Article
Multidisciplinary Sciences
Simon Horsburgh, Katrina Sharples, David Barson, Jiaxu Zeng, Lianne Parkin
Summary: The study reveals a dynamic pattern of discontinuation and reinitiation in patients using metformin monotherapy, with significant periods of non-use being common. Discontinuation and reinitiation varied based on age, ethnicity, and other person- and healthcare-related factors, highlighting the need for interventions to improve adherence in specific populations.
Article
Physiology
Yasufumi Seki, Satoshi Morimoto, Shihori Kimura, Noriyoshi Takano, Kaoru Yamashita, Kanako Bokuda, Nobukazu Sasaki, Daisuke Watanabe, Atsuhiro Ichihara
Summary: Aliskiren monotherapy did not show any superiority to amlodipine monotherapy on VFA, estimated glomerular filtration rates, or urinary albumin excretion in obese or type 2 diabetic hypertensive patients.
KIDNEY & BLOOD PRESSURE RESEARCH
(2023)
Review
Pharmacology & Pharmacy
Joseph G. G. Timmons, Lucy Littlejohn, James G. G. Boyle, John R. R. Petrie
Summary: Although there have been many advances in the treatment of type 1 diabetes, optimal glycemic control is still only achieved in a minority. Adjunct therapy, including insulin analogues, SGLT2 inhibitors, GLP-1 receptor agonists, and others, is being investigated as a strategy to improve outcomes in type 1 diabetes.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Article
Biochemistry & Molecular Biology
Mark Agostino, Jennifer Rooney, Lakshini Herat, Jennifer Matthews, Allyson Simonds, Susan E. Northfield, Denham Hopper, Markus P. Schlaich, Vance B. Matthews
Summary: The study found that TNFSF14-derived molecules positively regulate glucose homeostasis and lipid metabolism, potentially opening a completely novel therapeutic pathway for treating obesity and T2D.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Endocrinology & Metabolism
Thomas F. Dejgaard, Bernt J. von Scholten, Erik Christiansen, Frederik F. Kreiner, Lars Bardtrum, Matthias von Herrath, Chantal Mathieu, Sten Madsbad
Summary: In both the ADJUNCT ONE and ADJUNCT TWO trials, the efficacy and glycaemic safety of liraglutide did not depend on subgroups, with residual beta-cell function being identified as the only variable impacting the effect of GLP-1 RAs in T1D. This supports a role for GLP-1 RAs as adjuncts to insulin in T1D, warranting further study.
DIABETES OBESITY & METABOLISM
(2021)
Article
Medicine, General & Internal
Yan-Yu Lin, Shuen-Fu Weng, Chung-Huei Hsu, Chen-Ling Huang, Yu-Pei Lin, Min-Chun Yeh, A-Young Han, Yu-Shan Hsieh
Summary: This study compared the effects of metformin-based dual therapy and triple therapy on glycemic control and lipid profile changes in Taiwanese patients with T2DM. The results showed that the combination of metformin and DPP4 and SGLT2 inhibitor therapy was more effective in reducing LDL-C and improving total cholesterol and HDL-C compared to metformin monotherapy. Dual therapy of metformin and linagliptin had a better glycemic control ability than metformin monotherapy, while triple therapy of empagliflozin and linagliptin had a better glycemic control ability than linagliptin dual therapy. Additionally, triple therapy of dapagliflozin and saxagliptin had a better lipid control ability than dapagliflozin dual therapy.
FRONTIERS IN MEDICINE
(2022)
Article
Endocrinology & Metabolism
Summary: The American Diabetes Association's Standards of Medical Care in Diabetes consist of clinical practice recommendations, components of diabetes care, and tools for evaluating quality of care. The committee is responsible for updating the standards annually, and monitoring for the development of type 2 diabetes in those with prediabetes is suggested. Screening for prediabetes in high-risk patients is recommended as it provides an effective means of preventing type 2 diabetes.
Review
Medicine, Research & Experimental
Simeon I. Taylor, Zhinous Shahidzadeh Yazdi, Amber L. Beitelshees
Summary: Diabetes mellitus is a significant public health issue, with pharmacotherapy aiming to prevent complications. Clinical trials have shown that intensive glycemic control can slow the progression of complications, with some drugs also demonstrating cardiovascular benefits and slowed progression of diabetic kidney disease.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Endocrinology & Metabolism
Laura del Bosque-Plata, Eduardo Martinez-Martinez, Miguel Angel Espinoza-Camacho, Claudia Gragnoli
Summary: TCF7L2 is the most potent locus for type 2 diabetes (T2D) risk and is consistently associated with the disease across diverse populations with different genetic origins. The exact mechanisms by which TCF7L2 affects T2D are still not well understood.
Article
Endocrinology & Metabolism
Julie Dubourg, Pascale Fouqueray, Damien Quinslot, Jean-Marie Grouin, Kohei Kaku
Summary: The study evaluated the safety and efficacy of imeglimin for 52 weeks as monotherapy or combination therapy in Japanese patients with type 2 diabetes. Results showed well-tolerated and effective outcomes in both treatment approaches.
DIABETES OBESITY & METABOLISM
(2022)
Review
Biochemistry & Molecular Biology
Alina Kurylowicz
Summary: Given the significant social and financial costs associated with diabetes management, efforts need to be made to improve prevention and treatment methods. This narrative review focuses on the therapeutic potential of isoflavones in diabetes prevention and treatment, summarizing their molecular mechanisms, preclinical studies, epidemiological studies, and clinical trials. The review also discusses the effects of isoflavones on organs involved in diabetes pathogenesis, as well as other organs contributing to glucose homeostasis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)